Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASpiRE: SX-682 and Apalutamide in mCRPC
NCT07002320Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Apr 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of SX-682 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by The Institute of Cancer Research. Started Apr 2025; status: recruiting.
02
Drugs
SX-682
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07002320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002320.